Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.28 - $7.57 $2.18 Million - $3.13 Million
-413,300 Reduced 58.52%
292,900 $2.02 Million
Q2 2024

Aug 15, 2024

BUY
$5.89 - $9.31 $687,363 - $1.09 Million
116,700 Added 19.8%
706,200 $5.23 Million
Q1 2024

May 07, 2024

SELL
$6.05 - $9.74 $601,370 - $968,156
-99,400 Reduced 14.43%
589,500 $4.3 Million
Q4 2023

Feb 14, 2024

BUY
$3.29 - $6.64 $2.12 Million - $4.27 Million
643,000 Added 1400.87%
688,900 $4.27 Million
Q3 2023

Nov 14, 2023

SELL
$3.3 - $4.83 $689,700 - $1.01 Million
-209,000 Reduced 81.99%
45,900 $187,000
Q2 2023

Aug 11, 2023

SELL
$3.23 - $4.95 $3.22 Million - $4.94 Million
-998,300 Reduced 79.66%
254,900 $864,000
Q1 2023

May 16, 2023

SELL
$2.68 - $4.79 $87,636 - $156,633
-32,700 Reduced 2.54%
1,253,200 $6 Million
Q4 2022

Feb 14, 2023

BUY
$1.22 - $2.85 $520,086 - $1.21 Million
426,300 Added 49.59%
1,285,900 $3.66 Million
Q3 2022

Nov 14, 2022

BUY
$0.59 - $1.44 $192,104 - $468,864
325,600 Added 60.97%
859,600 $1.02 Million
Q2 2022

Aug 15, 2022

BUY
$0.51 - $1.17 $146,166 - $335,322
286,600 Added 115.84%
534,000 $315,000
Q1 2022

May 16, 2022

SELL
$0.65 - $1.18 $258,830 - $469,876
-398,200 Reduced 61.68%
247,400 $265,000
Q4 2021

Feb 14, 2022

BUY
$0.86 - $1.7 $541,800 - $1.07 Million
630,000 Added 4038.46%
645,600 $710,000
Q3 2021

Nov 15, 2021

SELL
$1.27 - $8.17 $42,799 - $275,329
-33,700 Reduced 68.36%
15,600 $21,000
Q2 2021

Aug 11, 2021

BUY
$6.55 - $8.98 $174,230 - $238,868
26,600 Added 117.18%
49,300 $374,000
Q1 2020

May 15, 2020

SELL
$4.35 - $8.79 $602,040 - $1.22 Million
-138,400 Reduced 85.91%
22,700 $129,000
Q4 2019

Feb 14, 2020

SELL
$4.23 - $8.29 $126,477 - $247,870
-29,900 Reduced 15.65%
161,100 $1.21 Million
Q3 2019

Nov 14, 2019

BUY
$2.15 - $6.28 $410,650 - $1.2 Million
191,000 New
191,000 $898,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $769M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.